Why the study?
SGLT2 inhibitors show promise in heart failure, but their benefits and side effects in heart failure patients with reduced ejection fraction needed quantification.
Do SGLT2 inhibitors reduce hospitalization due to heart failure and cardiovascular mortality in patients with heart failure?
Population
Heart failure patients with a reduced ejection fraction
Comparison
SGLT2 inhibitors vs comparator
Design
Systematic review and meta-analysis of randomized controlled trials
Authors
Loading...
Supports SGLT2i use in HFrEF to reduce CV events; reinforces consensus from prior RCTs.
Do SGLT2 inhibitors reduce hospitalization due to heart failure and cardiovascular mortality in patients with heart failure?
SGLT2 inhibitors offer a promising role in reducing cardiovascular complications in heart failure patients without significantly increasing adverse effects such as amputations, fractures, or UTIs.
Waseem et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: